CN101942413B - 出生缺陷细胞库及其构建方法 - Google Patents
出生缺陷细胞库及其构建方法 Download PDFInfo
- Publication number
- CN101942413B CN101942413B CN200910152257.8A CN200910152257A CN101942413B CN 101942413 B CN101942413 B CN 101942413B CN 200910152257 A CN200910152257 A CN 200910152257A CN 101942413 B CN101942413 B CN 101942413B
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- birth defect
- inborn defect
- defect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000032170 Congenital Abnormalities Diseases 0.000 title claims abstract description 28
- 230000007698 birth defect Effects 0.000 title claims abstract description 28
- 238000010276 construction Methods 0.000 title claims abstract description 7
- 108020004414 DNA Proteins 0.000 claims abstract description 25
- 238000011160 research Methods 0.000 claims abstract description 19
- 239000007788 liquid Substances 0.000 claims abstract description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 14
- 102000004877 Insulin Human genes 0.000 claims abstract description 9
- 108090001061 Insulin Proteins 0.000 claims abstract description 9
- 239000000463 material Substances 0.000 claims abstract description 9
- 102000029816 Collagenase Human genes 0.000 claims abstract description 8
- 108060005980 Collagenase Proteins 0.000 claims abstract description 8
- 229960002424 collagenase Drugs 0.000 claims abstract description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 7
- 108010061982 DNA Ligases Proteins 0.000 claims abstract description 5
- 102000012410 DNA Ligases Human genes 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 170
- 230000007547 defect Effects 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 26
- 235000015097 nutrients Nutrition 0.000 claims description 14
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 101710128836 Large T antigen Proteins 0.000 claims description 9
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 8
- 244000309466 calf Species 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 210000002966 serum Anatomy 0.000 claims description 8
- 230000012010 growth Effects 0.000 claims description 7
- 238000001638 lipofection Methods 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000008676 import Effects 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 108020005202 Viral DNA Proteins 0.000 claims description 3
- 210000004381 amniotic fluid Anatomy 0.000 claims description 3
- 230000002950 deficient Effects 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 3
- 238000012216 screening Methods 0.000 claims description 3
- 238000001890 transfection Methods 0.000 abstract description 7
- 241000588724 Escherichia coli Species 0.000 abstract description 5
- 238000007710 freezing Methods 0.000 abstract description 4
- 230000008014 freezing Effects 0.000 abstract description 4
- 239000000725 suspension Substances 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 238000000338 in vitro Methods 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 abstract 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 239000012894 fetal calf serum Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 22
- 238000001556 precipitation Methods 0.000 description 9
- 239000006285 cell suspension Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000012637 gene transfection Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 201000005249 lung adenocarcinoma Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 201000010374 Down Syndrome Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000000349 chromosome Anatomy 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000013016 damping Methods 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 3
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 206010044688 Trisomy 21 Diseases 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 201000005296 lung carcinoma Diseases 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 3
- 230000002688 persistence Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000009609 prenatal screening Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 241000714205 Woolly monkey sarcoma virus Species 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 238000003793 prenatal diagnosis Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229940123373 Adenovirus E1A gene Drugs 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 102100021257 Beta-secretase 1 Human genes 0.000 description 1
- 101710150192 Beta-secretase 1 Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015108 Epstein-Barr virus infection Diseases 0.000 description 1
- 101150030514 GPC1 gene Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 101150014615 LCC2 gene Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000694873 Paralichthyidae Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000555922 Potamogeton crispus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102000016941 Rho Guanine Nucleotide Exchange Factors Human genes 0.000 description 1
- 108010053823 Rho Guanine Nucleotide Exchange Factors Proteins 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100035254 Sodium- and chloride-dependent GABA transporter 3 Human genes 0.000 description 1
- 101710104417 Sodium- and chloride-dependent GABA transporter 3 Proteins 0.000 description 1
- 208000037280 Trisomy Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000005770 chromosome separation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000004489 deciduous teeth Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001985 kidney epithelial cell Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000004540 pour-on Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 239000007320 rich medium Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910152257.8A CN101942413B (zh) | 2009-07-07 | 2009-07-07 | 出生缺陷细胞库及其构建方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910152257.8A CN101942413B (zh) | 2009-07-07 | 2009-07-07 | 出生缺陷细胞库及其构建方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101942413A CN101942413A (zh) | 2011-01-12 |
CN101942413B true CN101942413B (zh) | 2015-02-11 |
Family
ID=43434625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910152257.8A Active CN101942413B (zh) | 2009-07-07 | 2009-07-07 | 出生缺陷细胞库及其构建方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101942413B (zh) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104060329A (zh) * | 2013-03-19 | 2014-09-24 | 翁炳焕 | 一种染色体核型分析永生化质控细胞库及其构建方法 |
CN104059883A (zh) * | 2013-03-19 | 2014-09-24 | 翁炳焕 | 一种常见染色体数目异常诊断质控细胞株及其制备方法 |
CN104059882A (zh) * | 2013-03-19 | 2014-09-24 | 翁炳焕 | 一种荧光原位杂交hTERT转染室间质评细胞系及其制备方法 |
CN104060328A (zh) * | 2013-03-19 | 2014-09-24 | 翁炳焕 | 一种染色体异常核型质控细胞库及其构建方法 |
CN104059885A (zh) * | 2013-03-19 | 2014-09-24 | 翁炳焕 | 一种分子遗传学诊断hTERT和SV40转导质控细胞及其制备方法 |
CN104419681A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | SV40LT和hTERT基因转导构建Turner综合征细胞模型及其细胞库 |
CN104419676A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | hTERT基因重组构建唐氏综合征细胞模型及其细胞库 |
CN104419662A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | SV40LT及hTERT基因转染构建房间隔缺损细胞模型及其细胞库 |
CN104419675A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 重组hTERT构建先天性心脏病室间隔缺损细胞模型及其细胞库 |
CN104419680A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 导入SV40LT和hTERT重组基因构建神经管缺陷细胞模型及其细胞库 |
CN104419723A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | SV40LT和hTERT基因重组构建T淋巴细胞模型及其细胞库 |
CN104419669A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 重组sv40基因构建克氏综合征细胞模型及其细胞库 |
CN104419667A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 导入sv40t基因构建神经管缺陷细胞模型及其细胞库 |
CN104419725A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 转染SV40LT和hTERT重组子构建巨核细胞模型及其细胞库 |
CN104419679A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | hTERT和SV40LT基因诱导构建克氏综合征细胞模型及其细胞库 |
CN104419727A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | hTERT重组子诱导构建神经管缺陷细胞模型及其细胞库 |
CN104419722A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 导入hTERT构建Turner综合征细胞模型及其细胞库 |
CN104419671A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | Sv40大t基因诱导构建先天性心脏病房间隔缺损细胞模型及其细胞库 |
CN104419677A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | hTERT转基因构建18-三体综合征细胞模型及其细胞库 |
CN104419730A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | hTERT转染构建染色体缺失猫叫综合征细胞模型及其细胞库 |
CN104419670A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | Sv40基因重组构建巨核细胞模型及其细胞库 |
CN104419674A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | hTERT诱导构建先天性心脏病房间隔缺损细胞模型及其细胞库 |
CN104419682A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 重组SV40LT和hTERT基因构建21-三体综合征细胞模型及其细胞库 |
CN104419665A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | Sv40lt介导唐氏综合征细胞模型及其细胞库的构建 |
CN104419720A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | SV40LT和hTERT介导先天性心脏病室间隔缺损细胞模型及其细胞库的构建 |
CN104419664A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | SV40T基因诱导构建Turner综合征细胞模型及其细胞库 |
CN104419724A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | Sv40lt基因诱导构建t淋巴细胞模型及其细胞库 |
CN104419666A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 猴肾病毒40大t基因转染构建染色体易位细胞模型及其细胞库 |
CN104419729A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 转染hTERT和SV40LT构建染色体易位细胞模型及其细胞库 |
CN104419684A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 转染sv40lt基因构建18-三体综合征细胞模型及其细胞库 |
CN104419668A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | Sv40lt重组构建染色体缺失猫叫综合征细胞模型及其细胞库 |
CN104419663A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | hTERT重组构建染色体易位细胞模型及其细胞库 |
CN104419672A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 转导sv40lt抗原基因构建先天性心脏病室间隔缺损细胞模型及其细胞库 |
CN104419678A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 导入hTERT和SV40LT重组子构建爱德华综合征细胞模型及其细胞库 |
CN104419728A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | hTERT及SV40LT联合介导构建猫叫综合征细胞模型及其细胞库 |
CN104419673A (zh) * | 2013-09-01 | 2015-03-18 | 翁炳焕 | 转染hTERT重组基因构建克氏综合征细胞模型及其细胞库 |
CN108060138A (zh) * | 2018-02-05 | 2018-05-22 | 翁炳焕 | 一种无创产前基因检测质控标准品及其制备 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1336431A (zh) * | 2001-08-23 | 2002-02-20 | 北京大学人民医院 | 人卵巢癌永生化细胞株的建立 |
CN1916183A (zh) * | 2005-08-19 | 2007-02-21 | 翁炳焕 | 染色体核型分析质控细胞建株及质控方法 |
WO2007079183A3 (en) * | 2005-12-29 | 2007-11-15 | Anthrogenesis Corp | Placental stem cell populations |
CN101310014A (zh) * | 2005-11-16 | 2008-11-19 | 塞维克制药有限责任公司 | 制备永久人细胞系的方法 |
-
2009
- 2009-07-07 CN CN200910152257.8A patent/CN101942413B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1336431A (zh) * | 2001-08-23 | 2002-02-20 | 北京大学人民医院 | 人卵巢癌永生化细胞株的建立 |
CN1916183A (zh) * | 2005-08-19 | 2007-02-21 | 翁炳焕 | 染色体核型分析质控细胞建株及质控方法 |
CN101310014A (zh) * | 2005-11-16 | 2008-11-19 | 塞维克制药有限责任公司 | 制备永久人细胞系的方法 |
WO2007079183A3 (en) * | 2005-12-29 | 2007-11-15 | Anthrogenesis Corp | Placental stem cell populations |
Also Published As
Publication number | Publication date |
---|---|
CN101942413A (zh) | 2011-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101942413B (zh) | 出生缺陷细胞库及其构建方法 | |
CN112760293A (zh) | 一种无异源血清3d培养msc干细胞制备高活性外泌体的方法 | |
CN116836933B (zh) | 肝胆癌类器官培养液、培养试剂组合及培养方法 | |
CN117417964A (zh) | 一种绵羊乳腺上皮细胞系及其构建方法、用途 | |
CN108034634B (zh) | 一种从经血中分离宫内膜间充质干细胞的方法 | |
CN104060329A (zh) | 一种染色体核型分析永生化质控细胞库及其构建方法 | |
CN104419676A (zh) | hTERT基因重组构建唐氏综合征细胞模型及其细胞库 | |
CN109609463A (zh) | 一种宫颈癌肿瘤原代细胞分离及培养方法 | |
CN105219732B (zh) | 一种永生化人肝癌血管内皮细胞系及其制备方法和应用 | |
CN104419677A (zh) | hTERT转基因构建18-三体综合征细胞模型及其细胞库 | |
CN104419727A (zh) | hTERT重组子诱导构建神经管缺陷细胞模型及其细胞库 | |
CN104419684A (zh) | 转染sv40lt基因构建18-三体综合征细胞模型及其细胞库 | |
CN117138121B (zh) | 一种减少破坏提高纯度的自体脂肪移植方法 | |
CN104419682A (zh) | 重组SV40LT和hTERT基因构建21-三体综合征细胞模型及其细胞库 | |
CN104419729A (zh) | 转染hTERT和SV40LT构建染色体易位细胞模型及其细胞库 | |
CN104419663A (zh) | hTERT重组构建染色体易位细胞模型及其细胞库 | |
CN104419720A (zh) | SV40LT和hTERT介导先天性心脏病室间隔缺损细胞模型及其细胞库的构建 | |
CN104419662A (zh) | SV40LT及hTERT基因转染构建房间隔缺损细胞模型及其细胞库 | |
CN104419680A (zh) | 导入SV40LT和hTERT重组基因构建神经管缺陷细胞模型及其细胞库 | |
CN117625549A (zh) | 一种大鼠水动力肝癌细胞系及应用 | |
CN104419674A (zh) | hTERT诱导构建先天性心脏病房间隔缺损细胞模型及其细胞库 | |
CN104419672A (zh) | 转导sv40lt抗原基因构建先天性心脏病室间隔缺损细胞模型及其细胞库 | |
CN104419666A (zh) | 猴肾病毒40大t基因转染构建染色体易位细胞模型及其细胞库 | |
CN104419726A (zh) | hTERT介导T淋巴细胞模型及其细胞库的构建 | |
CN104419675A (zh) | 重组hTERT构建先天性心脏病室间隔缺损细胞模型及其细胞库 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: ZHEJIANG TONGCHUANG INSPECTION TECHNOLOGY DEVELOPM Free format text: FORMER OWNER: WENG BINGHUAN Effective date: 20150817 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150817 Address after: Green Ting Road Yuhang District Cang Qian street of Hangzhou city Zhejiang province 310006 No. 1 Building 3 room 113 Patentee after: Zhejiang Tongchuang Inspection Technology Development Co. Ltd. Address before: 310006 birth defects laboratory, Zhejiang University (affiliated obstetrics and Gynecology Hospital), 2 bachelor Road, Hangzhou, Zhejiang Patentee before: Weng Binghuan |
|
CP01 | Change in the name or title of a patent holder |
Address after: Green Ting Road Yuhang District Cang Qian street of Hangzhou city Zhejiang province 310006 No. 1 Building 3 room 113 Patentee after: Zhejiang Tongchuang Medical Technology Co Ltd Address before: Green Ting Road Yuhang District Cang Qian street of Hangzhou city Zhejiang province 310006 No. 1 Building 3 room 113 Patentee before: Zhejiang Tongchuang Inspection Technology Development Co. Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171222 Address after: 310000 room 672, No. 405 and 501, No. 672, No. 3, Huazhong Nan Lu, Xiacheng City, Zhejiang Patentee after: Hangzhou co Genesis Laboratory Laboratory Limited Address before: Green Ting Road Yuhang District Cang Qian street of Hangzhou city Zhejiang province 310006 No. 1 Building 3 room 113 Patentee before: Zhejiang Tongchuang Medical Technology Co Ltd |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Birth defect cell bank and construction method thereof Effective date of registration: 20200630 Granted publication date: 20150211 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU TONGCHUANG MEDICAL EXAMINATION LABORATORY Co.,Ltd. Registration number: Y2020330000421 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220117 Granted publication date: 20150211 Pledgee: Hangzhou High-tech Financing Guarantee Co.,Ltd. Pledgor: HANGZHOU TONGCHUANG MEDICAL EXAMINATION LABORATORY Co.,Ltd. Registration number: Y2020330000421 |